DATA from clinical trials evaluating anti-tNF agents Three anti-TNF agents have been studied and two of these agents are approved by the FDA for the treatment of AS: etanercept, infliximab and ...

2 In our clinical experience, approximately 20% of patients with moderate-to-severe psoriasis are currently treated with anti-TNF agents including etanercept, infliximab and adalimumab.

One case series has demonstrated that patients with Takayasu's arteritis may respond to infliximab or etanercept when they have failed conventional immunosuppression. Monoclonal antibodies to CD20 ...

skin or joint infections and severe leucopenia Etanercept (Enbrel®) Injection site reactions and upper respiratory tract infections Serious bacterial infections, unusual infections (tuberculosis ...

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; ...

Rheumatoid arthritis – adlimumab, etanercept, infliximab, certolizumab pegol, golumumab, abatacept and tocilizumab [in progress, ID537] TA247 Tocilizumab for the treatment of rheumatoid arthritis ...